Literature DB >> 33320182

Effect of a novel animal milk oligosaccharide biosimilar on macronutrient digestibility and gastrointestinal tolerance, fecal metabolites, and fecal microbiota of healthy adult cats.

Patrícia M Oba1, Anne H Lee1, Sara Vidal2, Romain Wyss2, Yong Miao2, Yemi Adesokan2, Kelly S Swanson1,3,4.   

Abstract

GNU100 is a novel animal milk oligosaccharide (AMO) biosimilar. In a recent in vitro fermentation study, GNU100 was shown to be fermentable by feline gastrointestinal microbiota and lead to increased short-chain fatty acid production. Our objectives herein were to evaluate the palatability, safety, and gastrointestinal tolerance of GNU100 in healthy adult cats. Exploratory end-points were measured to assess utility. In study 1, 20 adult cats were used to test the palatability of diets containing 0% or 1% GNU100. In study 2, 32 (mean age = 1.9 yr; mean body weight = 4.6 kg) male (n = 12) and female (n = 20) adult cats were used in a completely randomized design. After a 2-wk baseline, cats were assigned to one of the following treatment groups and fed for 26 wk: control (CT, no GNU100), low dose (LD, 0.5% GNU100), medium dose (MD, 1.0% GNU100), and high dose (HD, 1.5% GNU100). On weeks 2, 4, and 26, fresh fecal samples were collected for the measurement of stool quality and immune and inflammatory markers and on weeks 2 and 4 for microbiota and metabolites. On week 4, total feces were collected to measure apparent total tract macronutrient digestibility. On weeks 2, 4, and 26, blood samples were collected for serum chemistry, hematology, and inflammatory marker measurement. The palatability test showed that 1% GNU100 was strongly preferred (P < 0.05), with GNU100 having a 17.6:1 consumption ratio compared with control. In the long-term study, all cats remained healthy, without any signs of gastrointestinal intolerance or illness. All diets were well accepted, resulting in similar (P > 0.05) food intake, fecal characteristics, immunoglobulin A, and calprotectin, and dry matter, organic matter, fat, and crude protein digestibilities. Fecal butyrate was greater (P = 0.02) in cats fed HD than cats fed LD or MD. Fecal indole was lower (P = 0.02) in cats fed HD than cats fed LD. Cats fed CT had a higher (P = 0.003) relative abundance of Actinobacteria than cats fed LD. The relative abundance of Peptococcus was impacted by diet and time. At 4 wk, Campylobacter was lower in fecal samples of cats fed HD. Overall, the data suggest that dietary GNU100 supplementation was highly palatable, well tolerated, did not cause detrimental effects on fecal quality or nutrient digestibility, increased fecal butyrate concentrations, and reduced fecal indole concentrations, supporting the safety of GNU100 for inclusion in feline diets and suggesting potential benefits on gastrointestinal health of cats.
© The Author(s) 2020. Published by Oxford University Press on behalf of the American Society of Animal Science. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  feline nutrition; gastrointestinal functionality; microbiome; milk oligosaccharides; nutrient digestibility

Mesh:

Substances:

Year:  2021        PMID: 33320182      PMCID: PMC7799586          DOI: 10.1093/jas/skaa399

Source DB:  PubMed          Journal:  J Anim Sci        ISSN: 0021-8812            Impact factor:   3.159


  81 in total

1.  Utilization of major fucosylated and sialylated human milk oligosaccharides by isolated human gut microbes.

Authors:  Zhuo-Teng Yu; Ceng Chen; David S Newburg
Journal:  Glycobiology       Date:  2013-09-07       Impact factor: 4.313

2.  Phenol toxicity and conjugation in human colonic epithelial cells.

Authors:  G Pedersen; J Brynskov; T Saermark
Journal:  Scand J Gastroenterol       Date:  2002-01       Impact factor: 2.423

3.  Effects of dietary flax seed and sunflower seed supplementation on normal canine serum polyunsaturated fatty acids and skin and hair coat condition scores.

Authors:  C A Rees; J E Bauer; W J Burkholder; R A Kennis; B L Dunbar; K E Bigley
Journal:  Vet Dermatol       Date:  2001-04       Impact factor: 1.589

Review 4.  Oligosaccharides in human milk: structural, functional, and metabolic aspects.

Authors:  C Kunz; S Rudloff; W Baier; N Klein; S Strobel
Journal:  Annu Rev Nutr       Date:  2000       Impact factor: 11.848

Review 5.  Campylobacteriosis in dogs and cats: a review.

Authors:  E Acke
Journal:  N Z Vet J       Date:  2018-05-23       Impact factor: 1.628

6.  Human milk--derived oligosaccharides and plant-derived oligosaccharides stimulate cytokine production of cord blood T-cells in vitro.

Authors:  Thomas Eiwegger; Bernd Stahl; Joachim Schmitt; Günther Boehm; Marianne Gerstmayr; Josefa Pichler; Eleonora Dehlink; Christine Loibichler; Radvan Urbanek; Zsolt Szépfalusi
Journal:  Pediatr Res       Date:  2004-08-04       Impact factor: 3.756

7.  The human milk oligosaccharide 2'-fucosyllactose attenuates the severity of experimental necrotising enterocolitis by enhancing mesenteric perfusion in the neonatal intestine.

Authors:  Misty Good; Chhinder P Sodhi; Yukihiro Yamaguchi; Hongpeng Jia; Peng Lu; William B Fulton; Laura Y Martin; Thomas Prindle; Diego F Nino; Qinjie Zhou; Congrong Ma; John A Ozolek; Rachael H Buck; Karen C Goehring; David J Hackam
Journal:  Br J Nutr       Date:  2016-09-09       Impact factor: 3.718

8.  In vitro fermentation characteristics of select nondigestible oligosaccharides by infant fecal inocula.

Authors:  Brittany M Vester Boler; Mariana C Rossoni Serao; Trevor A Faber; Laura L Bauer; JoMay Chow; Michael R Murphy; George C Fahey
Journal:  J Agric Food Chem       Date:  2013-02-20       Impact factor: 5.279

Review 9.  Sialic acid is an essential nutrient for brain development and cognition.

Authors:  Bing Wang
Journal:  Annu Rev Nutr       Date:  2009       Impact factor: 11.848

10.  The fecal microbiome in cats with diarrhea.

Authors:  Jan S Suchodolski; Mary L Foster; Muhammad U Sohail; Christian Leutenegger; Erica V Queen; Jörg M Steiner; Stanley L Marks
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.